NCT00730795View on ClinicalTrials.gov

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2004

Conditions

Tuberculosis (TB)

Interventions

BIOLOGICAL

GSK's candidate Mycobacterium tuberculosis vaccine 692342

Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)

Trial Locations (1)

9843

GSK Clinical Trials Call Center, Tacoma

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Corixa Corporation

All Listed Sponsors

collaborator

Corixa Corporation

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT00730795 - Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults | Biotech Hunter | Biotech Hunter